Medpace Holdings, Inc. (MEDP)

NASDAQ: MEDP · IEX Real-Time Price · USD
174.44
-2.39 (-1.35%)
At close: Aug 18, 2022 4:00 PM
174.00
-0.44 (-0.25%)
After-hours: Aug 18, 2022 5:01 PM EDT
-1.35%
Market Cap 5.41B
Revenue (ttm) 1.29B
Net Income (ttm) 209.28M
Shares Out 31.00M
EPS (ttm) 5.74
PE Ratio 30.39
Forward PE 40.98
Dividend n/a
Ex-Dividend Date n/a
Volume 145,650
Open 177.24
Previous Close 176.83
Day's Range 173.19 - 177.24
52-Week Range 126.95 - 231.00
Beta 1.43
Analysts Buy
Price Target 149.94 (-14.0%)
Earnings Date Jul 25, 2022

About MEDP

Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. It offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. The company also provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmac... [Read more...]

Industry Life Sciences Tools & Services
IPO Date Aug 11, 2016
CEO August Troendle
Employees 4,800
Stock Exchange NASDAQ
Ticker Symbol MEDP
Full Company Profile

Financial Performance

In 2021, MEDP's revenue was $1.14 billion, an increase of 23.38% compared to the previous year's $925.93 million. Earnings were $181.85 million, an increase of 25.08%.

Financial Statements

Analyst Forecast

According to 11 analysts, the average rating for MEDP stock is "Buy." The 12-month stock price forecast is 149.94, which is a decrease of -14.04% from the latest price.

Price Target
$149.94
(-14.04% downside)
Analyst Consensus: Buy
Stock Forecasts

News

3 Reasons Growth Investors Will Love Medpace (MEDP)

Medpace (MEDP) possesses solid growth attributes, which could help it handily outperform the market.

These eight health-care stocks can keep you invested in the market with less worry

You're tempted to increase exposure to stocks because of the market's strength. But you're still gun shy because of the painful selloff.

Want $1 Million in Retirement? Invest $150,000 in These 3 Stocks and Wait a Decade

These healthcare stocks could help you retire early, offering impressive margins and promising growth potential.

Other symbols: DOCSVEEV

Medpace (MEDP) Q2 Earnings and Revenues Top Estimates

Medpace (MEDP) delivered earnings and revenue surprises of 8.96% and 1.29%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Medpace Holdings, Inc. Reports Second Quarter 2022 Results

CINCINNATI--(BUSINESS WIRE)--Medpace Holdings, Inc. (Nasdaq: MEDP) (“Medpace”) today announced financial results for the second quarter ended June 30, 2022. Second Quarter 2022 Financial Results Revenue...

Should You Buy Medpace (MEDP) Ahead of Earnings?

Medpace (MEDP) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

5 Stocks to Buy Ahead of Q2 Earnings Results Next Week

Five companies will report second-quarter 2022 earnings results next week. These are: EQT, MEDP, CR, HES and ZION.

Other symbols: CREQTHESZION

Stocks With Rising Relative Strength: Medpace

A Relative Strength Rating upgrade for Medpace shows improving technical performance. Will it continue?

Medpace (MEDP) Reports Next Week: Wall Street Expects Earnings Growth

Medpace (MEDP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

3 Top Stocks to Bet on for Superb Earnings Growth

Invest in stocks like Medpace (MEDP), Texas Pacific Land (TPL) & Delek US Holdings (DK) at the moment for solid earnings growth.

Other symbols: DKTPL

Here is Why Growth Investors Should Buy Medpace (MEDP) Now

Medpace (MEDP) could produce exceptional returns because of its solid growth attributes.

Medpace Holdings, Inc. to Report Second Quarter 2022 Financial Results on July 25, 2022

CINCINNATI--(BUSINESS WIRE)--Medpace Holdings, Inc. (Nasdaq: MEDP) (“Medpace”) today announced that it will report its second quarter 2022 financial results after the market close on Monday, July 25, 20...

Looking for a Growth Stock? 3 Reasons Why Medpace (MEDP) is a Solid Choice

Medpace (MEDP) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Is Medpace (MEDP) a Solid Growth Stock? 3 Reasons to Think " Yes "

Medpace (MEDP) could produce exceptional returns because of its solid growth attributes.

Medpace Posts Better Than Expected Q1 Earnings, Lifts FYY22 Profit Outlook

Medpace Holdings Inc's (NASDAQ: MEDP) Q1 revenue increased 27.3% Y/Y to $330.9 million, beating the consensus of $327.09 million. On a constant currency organic basis, revenue increased 28.1%.

Medpace (MEDP) Q1 Earnings and Revenues Surpass Estimates

Medpace (MEDP) delivered earnings and revenue surprises of 34.13% and 1.11%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Medpace Holdings, Inc. Reports First Quarter 2022 Results

CINCINNATI--(BUSINESS WIRE)--Medpace Holdings, Inc. (Nasdaq: MEDP) (“Medpace”) today announced financial results for the first quarter ended March 31, 2022. First Quarter 2022 Financial Results Revenue ...

Medpace Donation to Matthew 25: Ministries Funds Delivery of Relief Supplies to Ukraine

CINCINNATI--(BUSINESS WIRE)--Medpace (MEDP), a global clinical research organization (CRO), has partnered with Matthew 25: Ministries, a humanitarian and disaster relief organization, to fund aid shipme...

Medpace Holdings, Inc. to Report First Quarter 2022 Financial Results on April 25, 2022

CINCINNATI--(BUSINESS WIRE)--Medpace Holdings, Inc. (Nasdaq: MEDP) (“Medpace”) today announced that it will report its first quarter 2022 financial results after the market close on Monday, April 25, 20...

Down 18.4% in 4 Weeks, Here's Why You Should You Buy the Dip in Medpace (MEDP)

The heavy selling pressure might have exhausted for Medpace (MEDP) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in r...

Medpace (MEDP) Q4 Earnings Beat Estimates

Medpace (MEDP) delivered earnings and revenue surprises of 5.60% and 0.21%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Medpace Holdings, Inc. Reports Fourth Quarter and Full Year 2021 Results

CINCINNATI--(BUSINESS WIRE)--Medpace Holdings, Inc. (Nasdaq: MEDP) (“Medpace”) today announced financial results for the fourth quarter and full year ended December 31, 2021. Fourth Quarter and Full Yea...

Analysts Estimate Medpace (MEDP) to Report a Decline in Earnings: What to Look Out for

Medpace (MEDP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Medpace Holdings, Inc. to Report Fourth Quarter and Fiscal Year 2021 Financial Results on February 14, 2022

CINCINNATI--(BUSINESS WIRE)--Medpace Holdings, Inc. (Nasdaq: MEDP) (“Medpace”) today announced that it will report its fourth quarter and fiscal year 2021 financial results after the market close on Mon...

My 3 Favorite Under-the-Radar Healthcare Stocks for 2022

These smaller healthcare companies all have 10x potential for investors.

Other symbols: MEMLAB